Background: Biological complexity leads to significant variation in the survival of patients with stage I non-small-cell lung cancer (NSCLC). DNA damage response (DDR) pathways play a critical role in maintaining genomic stability and in the progression of NSCLC. Therefore, the development of a prognostic biomarker focusing on DDR pathways is an intriguing issue.
yield a survival advantage and was even harmful to the patients [7, 8] .
The DNA damage response (DDR) is a complex network of signaling pathways. Proteins involved in DDR pathways play crucial roles in maintaining genomic stability, thus suppressing tumor development or the progression of cancer as well as regulating cell cycle checkpoints [9] [10] [11] . Ataxia telangiectasia mutated (ATM), γH2AX, p53 binding protein 1 (53BP1), checkpoint kinase 2 (Chk2), mediator of DNA damage checkpoint protein 1 (MDC1), breast cancer susceptibility gene 1 (BRCA1), or excision repair cross-complementation 1 (ERCC1) are activated as a network and represent important assets in the repair of double-strand breaks when damage occurs [11] [12] [13] . The knowledge about DDR pathways is progressing rapidly; however, the exact mechanisms underlying this network require further elucidation. Among the many proteins involved in DDR pathways, the prognostic relevance of ERCC1 for stage I NSCLC was tested [14] . Notably, the information on the prognostic significance of proteins involved in DDR pathways is very limited.
In this study, we hypothesized that proteins involved in DDR pathways have effects on the survival of patients with pathological stage I NSCLC.
methods patients and tissue specimens
Consecutive patients with pathological stage I squamous cell carcinoma or adenocarcinoma were enrolled retrospectively from 11 university hospitals in South Korea (details provided in supplemental Figure S1 , available at Annals of Oncology online). Patients who received surgical resection between January 1997 and December 2005 were considered for this study. They were pathologically staged using the criteria of AJCC, sixth edition [15] . Inclusion criteria were as follows: (i) complete surgical removal of tumor (R0 resection); (ii) availability of formalin-fixed, paraffin-embedded (FFPE) primary lung cancer tissue blocks; and (iii) follow-up of >24 months after surgical resection. Patients who received limited resection, such as wedge resection or segmentectomy, any anticancer treatment prior to surgical resection, or had history of other cancers were excluded.
Information regarding smoking habits, Charlson comorbidity index score (CCIS), types of surgery, tumor size, and lymphatic or blood vessel invasion on the pathological specimens was collected. To increase the quality of the information, the reports of radiological examinations (chest computed tomography scan, positron emission tomography, etc.), surgical pathology, and clinical information for all patients were reviewed independently. All FFPE blocks were sent to a central laboratory (SuperBioChips, Seoul, South Korea) to construct tissue microarrays and for immunohistochemical staining. The study protocol was approved by the Institutional Review Boards of the university hospitals and informed consent by the patient was waived.
construction of tissue microarrays and immunohistochemistry
Slides of tumor samples stained with hematoxylin and eosin and matched FFPE samples with a marked representative area were reviewed. Core tissue biopsy specimens (2 mm in diameter) were obtained from individual FFPE samples (donor blocks) and arranged in a new recipient paraffin block (tissue array block) using a trephine apparatus. Each tissue array block contained up to 50 specimens, which allowed all 984 specimens to be contained in 20 array blocks. Serial sections (4 μm) from FFPE blocks were analyzed for protein expression. Among the proteins involved in DDR pathways, 11 commercially available antibodies against the wild-type and phosphorylated forms of each protein were chosen for ATM, ATMpS1981, γH2AX, 53BP1, 53BP1pS25, Chk2, Chk2pT68, MDC1, MDC1pS964, BRCA1pS1423, and ERCC1.
All immunohistochemical stainings were performed at the SuperBioChips Laboratories. Immunohistochemistry was performed using a Leica Bond-max automated immunostainer (Leica Microsystems, Newcastle, UK), according to the manufacturer's protocols. For antigen retrieval, slides were heated for 20 min at 100°C in antigen retrieval buffer ( pH 6.0 citrate buffer and pH 9.0 EDTA buffer). Endogenous biotin was blocked using the appropriate kit. Subsequently, slides were incubated with the primary antibody for 15 min. The dilution ratio and optimal concentration of retrieval buffer for each antibody are shown in supplemental Table S1 (available at Annals of Oncology online). Antibody binding was detected using the Bond Polymer Refined Detection kit (Leica Microsystems). Mayer's hematoxylin was used as the counterstain.
evaluation of immunohistochemistry
Samples containing >1000 malignant cells were considered for evaluation. For comparable semiquantitative estimation, the H score method used for ERCC1 was applied to the proteins included in this study [16] . Briefly, the percentage of tumor cells with positive nucleus staining on each tumor slide was calculated and was attributed a score of 0, 0.1, 0.5, or 1 for 0%, 1%-9%, 10%-49%, or >50% of stained tumor cells, respectively. The intensity of staining was recorded and given a score of 0, 1, 2, or 3. H scores were obtained by multiplying the proportion by the intensity of the staining. Each sample was reviewed independently by two pathologists (HJJ and LK) who were blinded to the clinicopathological variables and survival status. The mean H score was calculated for each sample. Subsequently, the median value of all mean H scores was used as a criterion for the classification of the expression of the 11 proteins as 'low' and 'high'.
survival measurements
The end point of this study was the estimation of overall survival from the date of surgery to death due to any cause. Dates of death were obtained principally from the revision of medical records. To increase the quality of the information regarding the survival status of patients lost to follow-up, this missing information was obtained by contacting the patients or their relatives by phone or mail (56 patients) or from the Ministry of Public Administration and Security, South Korea (87 patients).
statistical analysis
Expression of the proteins was dichotomized as low versus high. The chisquare test for heterogeneity was used to compare the distributions of the clinicopathological variables or levels of protein expression between squamous cell carcinoma and adenocarcinoma. Spearman's correlation test was used to evaluate potential relationships among the expression levels of the proteins. The effect of each clinicopathological variable or protein on overall survival was estimated using the Kaplan-Meier method and the logrank test. Hazards ratio (HR) adjusted for all clinicopathological variables with a log-rank P value <0.05 and the 95% confidence interval (CI) were estimated using the Cox proportional hazards model. To verify if the interaction of two proteins with a Cox P value <0.05 potentiated the effect, the effect of the combinations was analyzed after adjustment for all the variables. All significance testing was performed at a two-sided 0.05 level. All analyses were performed using the SAS software package (v. 9.1.3). Age, gender, smoking habits, CCIS, size of tumor, type of surgery, and lymphatic or blood vessel invasion were significantly associated with the survival of the patients. As expected, adjuvant chemotherapy was not a prognostic factor.
expression of proteins involved in DDR pathways according to histology
The level of expression of proteins (low versus high) was evaluated in the two distinct histologies ( Table 2 ). High expression of ATMpS1981, γH2AX, 53BP1, 53BP1pS25, Chk2, Chk2pT68, MDC1, BRCA1pS1423, and ERCC1 was observed in squamous cell carcinoma compared with adenocarcinoma. The expression of most proteins showed a significant correlation to each other (P < 0.001) (supplemental Table S3 , available at Annals of Oncology online).
effect of the proteins on the survival of stage I NSCLC patients
Patients with low expression of BRCA1pS1423 or ERCC1 exhibited a significantly worse survival compared with those combined effect of the proteins on the survival of the patients according to histology
The interactions between two proteins that were shown to have a significant prognostic effect in squamous cell carcinoma patients were analyzed to determine whether their combinations exert a synergistic or discriminative effect on the survival of the patients. 
discussion
The present study demonstrated that proteins involved in DDR pathways, such as γH2AX, Chk2pT68, and ERCC1, are strong prognostic factors for patients with pathological stage I squamous cell carcinoma, but not for adenocarcinoma patients.
Proteins involved in DDR pathways play an important role in suppressing carcinogenesis or the progression of lung cancer, as well as maintaining genomic stability [10, 11] . Therefore, they can be good candidates for a druggable target or a biomarker to predict prognosis or treatment response [17] .
Regarding the distribution of the expression of proteins between squamous cell carcinoma and adenocarcinoma, a study using 187 patients reported that expression of ERCC1 did not vary according to histology, gender, or smoking habits [14] . However, the result of another study using 130 patients with early stage NSCLC showed that high expression of ERCC1 was observed in squamous cell carcinoma compared with adenocarcinoma [18] . This finding was also reproduced in other studies using patients with operable or advanced stage NSCLC [16, 19] . In this study, the expression of proteins, including ERCC1, was explored, for the first time, in the 889 patients with pathological stage I disease. High expression of all the proteins, with the exception of ATM and MDC1pS964, was observed in squamous cell carcinoma compared with adenocarcinoma (Table 2) . A study using cell lines showed that smoking induced ATM activation and phosphorylation of H2AX on Ser 139 and Chk2 on Thr68 [20] . This can be regarded as similar to the process of repairing double-strand breaks and is in accordance with the results of this study showing that 87% of patients with squamous cell carcinoma were ever smokers. This indicates the presence of biological heterogeneity between the two histologies, in terms of DDR pathways. The significant correlations observed among the expression (low versus high) of almost all proteins listed in supplemental Table S3 (available at Annals of Oncology online) may represent clinical evidence for the role of the network of DDR pathways in stage I NSCLC. Histology is well recognized as an important phenotype in NSCLC patients [5, 21, 22] . As a phenotype, it also can be more reproducible and consistent compared with information on smoking habits, especially in this kind of retrospective study [23] . In this study, we evaluated the effect of the expression of DNA repair proteins in patients with squamous cell carcinoma or adenocarcinoma.
ERCC1 was shown to be prognostic in stage I NSCLC patients [14] . However, the prognostic relevance of most other DDR proteins has never been examined in patients. The consideration of the efficiency of the development of a biomarker may lead to a pathway-based approach that is more robust rather than that developed to use a single protein. This study showed that the proteins, or their combinations, had a significant prognostic effect that was significantly dependent on histology. In squamous cell carcinoma patients, low expression of γH2AX, Chk2pT68, or ERCC1 was associated with a 1.5-1.6 times higher risk for death compared with those exhibiting high expression (Table 3 ). The analysis of the combined effect of γH2AX, Chk2pT68, or ERCC1 showed that the patients with low/low expression levels exhibited a risk for death that was two times higher than that of patients with high/high expression levels (Figure 1 ; supplemental Table S4 , available at Annals of Oncology online). To know if cumulative effect of the three proteins is present, the patients were classified into scores of 0, 1, 2, or 3 of indicating numbers of the proteins with low expression (supplemental Table S5 , available at Annals of Oncology online). The risk for death increased as proportion as the score increased in squamous cell carcinoma. These results seem to be plausible, as low expression of these proteins can be original articles Annals of Oncology speculated to confer insufficient response to DNA damage, which is critical to maintaining genomic stability or for the progression of lung cancer. The stratum holding prognostic relevance from the combined effect, i.e. the percentage of patients with low/low or high/high expression levels of γH2AX, Chk2pT68, or ERCC1, was 62%-68% of the total patients.
Squamous cell carcinoma remains a major histology of lung cancer. However, it has been relatively neglected in the development of new drugs or biomarkers compared with adenocarcinoma. This may be attributed to the fact that it is considered a 'smart cancer' characterized by biological complexities compared with 'stupid cancer' characterized by oncogenic addiction such as the activation of EGFR mutation or EML4-ALK translocation, which is observed mostly in adenocarcinoma [5, 21] . In this regard, this study is important for the development of biomarkers that are specific for squamous cell carcinoma.
These results must be interpreted with some caution. This study may be limited potentially by its retrospective nature, as well as by not being validated using an independent cohort. We could not evaluate potential changes in smoking habits after surgery, which could affect the survival of patients. Nevertheless, we used every endeavor to increase the quality of the information on clinicopathological variables and identify the survival status of the patients. Moreover, we evaluated comorbidity (which is an important determinant of survival) as a confounding variable [24] . A large number of consecutive, pathological stage I patients were enrolled in this study. The sample size would be enough for this kind of study or for the interpretation using the subgroups of squamous cell carcinoma or adenocarcinoma. We used 8F1 as an antibody against ERCC1. Regarding the appropriateness of antibodies for ERCC1, 8F1 was compared with FL297; however, this ongoing issue warrants further validation in clinical samples [25] .
In summary, proteins involved in DDR pathways showed biological heterogeneity between squamous cell carcinoma and adenocarcinoma. Proteins such as γH2AX, Chk2pT68, and ERCC1 may be helpful for the classification of the squamous cell carcinoma patients into groups of low or high risk for death. 
